Health Personnel AttitudeNCT05120869

Healthcare Provider Human Papillomavirus Education and Professional Skills Intervention

A study testing Tailored HPV Education and Professional Skills Intervention Group in people with Health Personnel Attitude and Health Knowledge, Attitudes, Practice, run by University of Texas, El Paso at 2 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

Who is it for?: Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for: Health Personnel Attitude, Health Knowledge, Attitudes, Practice
What is being tested?: Tailored HPV Education and Professional Skills Intervention Group
Type of treatment: Lifestyle or therapy programme
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 161 participants
Where: 2 sitesUnited States
Study dates: 22 Dec 2023to 2 Dec 2024
Phase: Interventional
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 65 years
All sexes
Healthy volunteers accepted
Adult, Older adult

Who may be able to join

Current (in practice) or emerging (in training - medical student, resident, or fellow) healthcare provider
Working/training or living in the El Paso U.S.-Mexico Border Region (i.e., El Paso County, TX-Southern New Mexico)
Have the authorization to recommend/prescribe/administer the HPV vaccine

Who cannot join

Unaffiliated with the El Paso U.S.-Mexico Border Region (i.e., El Paso County, TX-Southern New Mexico)
Participation in Phases I or II of the larger research project [cross-sectional phases]
Does not identify as a current or emerging healthcare provider
Declines or is unable to participate in the full intervention and follow-up time-points
Unable to complete participation and activities in the English language

Trial locations and contacts

2 sites in 1 country.

United States2 sites

The University of Texas at El Paso, Border Biomedical Research Center
El Paso, Texas, 79968
Burrell College of Osteopathic Medicine
Las Cruces, New Mexico, 88001

Other trials in United States

About this study

Official title: Implementing Innovative and Strategic Approaches to Prevent and Mitigate the Deleterious Effects of HPV Across the Lifespan of Hispanics of Mexican Origin: Healthcare Provider Intervention

Healthcare providers (HCP) serving the El Paso U.S.-Mexico Border Region will be recruited to compare educational and professional skills interventions focused on the human papillomavirus (HPV). Our hypothesis is that improving provider knowledge and communication strategies about HPV and its vaccine will reduce hesitancy and increase uptake and completion among the populations they serve.

Read the detailed description

A sample of emerging [in training] and current [in practice] health professionals from the El Paso U.S.-Mexico Border Region will be recruited to participate in a human papillomavirus (HPV) educational and professional skills intervention. Hypothesis: improving provider knowledge and communication strategies about HPV and its vaccine will reduce hesitancy and increase uptake and completion among eligible individuals through a tailored multi-media intervention to strengthen providers' ability to discuss HPV and vaccination in an informed and culturally competent manner, and increase subsequent provider recommendations.

Conditions: Health Personnel Attitude, Health Knowledge, Attitudes, Practice
Being tested: Tailored HPV Education and Professional Skills Intervention Group, General HPV Education and Communication Skills Control Group
Keywords: Healthcare Professionals, Health Personnel Knowledge, Attitudes, Practices, Healthcare Skills and Training, Human Papillomavirus Vaccination, Human Papillomavirus Cancer Screening, HPV Cancer Prevention, HPV Cancer Mitigation, Sexual and Reproductive Health, U.S.-Mexico Border Health, Behavioral Research, Community Engaged Research, Health Disparities, Health Inequities, Social Determinants of Health, Coronavirus disease 2019 (COVID-19) Pandemic
Medical subject headings: Behavior, Coitus, COVID-19

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Tailored HPV Education and Professional Skills Intervention GroupBehavioural
The provider education and professional skills intervention will involve audio and visual content and will be delivered in the English language.
General HPV Education and Communication Skills Control GroupBehavioural
The general provider education intervention will involve audio and visual content and will be delivered in the English language.

Study groups in NCT05120869
Study group	Role	What they receive
Treatment	Experimental	A tailored HPV education and professional skills intervention. Receives: Behavioral: Tailored HPV Education and Professional Skills Intervention Group
Control	Active comparator	General/publicly available educational materials on HPV and communication skills. Receives: Behavioral: General HPV Education and Communication Skills Control Group

What is being measured

The primary outcome is the main question the study is designed to answer.

Healthcare Provider (HCP) Practices Scale Score
Healthcare provider practices score were assessed using an 8-item Healthcare Provider (HCP) Practices scale from the Healthcare Personnel Survey. The scale evaluated healthcare providers' HPV vaccine recommendation practices, HPV screening recommendation practices, and communication practices. Items were scored on a 5-point Likert scale ranging from Never (1) to Always (5).
Healthcare provider practices score is the average score over the 8 items, ranging from 1 to 5, with higher scores indicating better (more frequent engagement in recommended healthcare provider practices related to HPV prevention and screening).
Measured: Baseline
Healthcare Provider (HCP) Practices Scale Score
Healthcare provider practices score were assessed using an 8-item Healthcare Provider (HCP) Practices scale from the Healthcare Personnel Survey. The scale evaluated healthcare providers' HPV vaccine recommendation practices, HPV screening recommendation practices, and communication practices. Items were scored on a 5-point Likert scale ranging from Never (1) to Always (5).
Healthcare provider practices score is the average score over the 8 items, ranging from 1 to 5, with higher scores indicating better (more frequent engagement in recommended healthcare provider practices related to HPV prevention and screening).
Measured: 3 months post intervention
Healthcare Provider (HCP) Practices Scale Score
Healthcare provider practices score were assessed using an 8-item Healthcare Provider (HCP) Practices scale from the Healthcare Personnel Survey. The scale evaluated healthcare providers' HPV vaccine recommendation practices, HPV screening recommendation practices, and communication practices. Items were scored on a 5-point Likert scale ranging from Never (1) to Always (5).
Healthcare provider practices score is the average score over the 8 items, ranging from 1 to 5, with higher scores indicating better (more frequent engagement in recommended healthcare provider practices related to HPV prevention and screening).
Measured: 6 months post intervention

Secondary outcomes (2)

Human Papillomavirus (HPV) Attitude Score
Healthcare provider (HCP) attitudes toward HPV and the HPV vaccine. The 9-item HPV Vaccine Attitudes scale assessed perceived safety, perceived harm, and perceived effectiveness of the HPV vaccine. Items were rated on a 5-point Likert scale ranging from Strongly disagree (1) to Strongly agree (5).
A composite score was calculated by averaging responses across all assessed items, ranging from 1 to 5, with higher scores indicating more positive attitudes toward HPV vaccination.
Measured: Immediately post-intervention (0 months).
Human Papillomavirus (HPV) Knowledge Score
Healthcare provider (HCP) knowledge about HPV and the HPV vaccine was assessed using post-intervention scores from the Human Papillomavirus (HPV) Knowledge Scale included in the healthcare personnel survey. The 14-item HPV Knowledge scale consisted of True/False items scored as True (1) or False (0).
A composite score was calculated by averaging responses across all assessed items and multiplying the result by 100 to obtain a percentage score, ranging from 0 to 100, with higher scores indicating greater HPV-related knowledge.
Measured: Immediately post-intervention (0 months).

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

22 Dec 20232 Dec 2024

First posted15 Nov 2021
Study start22 Dec 2023
Primary completion2 Dec 2024
Study completion2 Dec 2024

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Publications (4)Papers the sponsor has linked to this study.
Other trials for Health Personnel AttitudeStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Other
Allocation: Randomised
Intervention model: Parallel groups
Model description: A parallel trial design will be used to examine the effectiveness of a tailored HPV education and professional skills intervention. Emerging and current healthcare providers will be randomly assigned to one of two conditions: 1) treatment condition in which they will receive a tailored Education and Professional Skills Intervention, and 2) control condition in which they will receive general, publicly available information about HPV and communication skills. Participants will then be followed over time and the responses will be compared between groups.
Masking: Double blind
Who is masked: Participant, Outcomes assessor
Enrolment: 161 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT05120869
Sponsor's protocol ID: 8321
Other IDs: 2U54MD007592-26
Status last verified: Aug 2026
First submitted: 6 Oct 2021
Last updated: 25 Aug 2026
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: Yes: Collected deidentified individual participant data (IPD), all IPD that underlie results in a publication.

Publications

Brabin L, Roberts SA, Farzaneh F, Kitchener HC. Future acceptance of adolescent human papillomavirus vaccination: a survey of parental attitudes. Vaccine. 2006 Apr 12;24(16):3087-94. doi: 10.1016/j.vaccine.2006.01.048. Epub 2006 Feb 9.
PubMed 16500736
McRee AL, Brewer NT, Reiter PL, Gottlieb SL, Smith JS. The Carolina HPV immunization attitudes and beliefs scale (CHIAS): scale development and associations with intentions to vaccinate. Sex Transm Dis. 2010 Apr;37(4):234-9. doi: 10.1097/OLQ.0b013e3181c37e15.
PubMed 19940807
Katz ML, Krieger JL, Roberto AJ. Human papillomavirus (HPV): college male's knowledge, perceived risk, sources of information, vaccine barriers and communication. J Mens Health. 2011 Oct 1;8(3):175-184. doi: 10.1016/j.jomh.2011.04.002.
PubMed 21966351
Martinez J, Cordero JI, Whitney M, LaRoche KL, Frietze G, Moya EM, Gosselink K. Web-Based Human Papillomavirus Education and Professional Skills Intervention for Health Care Providers: Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2025 Apr 3;14:e60790. doi: 10.2196/60790.
PubMed 40179382

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Not yet recruiting
Be Well at Work-Plus: A Depression and Physical Activity Intervention for Hospital Service Workers (Aim 3)
Depression, Physical Inactivity
Recruiting
Trial of Social Work Services in Fracture Clinic Setting
Orthopaedic Fractures, Socioeconomic Factors
Recruiting
A Study Of Resilience And Mental Well-Being Through Breathing Practice For Clinical Care Professionals
Burnout, Healthcare Workers, Breathing Exercises
Recruiting
Climate-Responsive Nutrition, WASH, and Heat Counselling for Maternal and Child Health in Sindh, Pakistan
Maternal Nutrition, Child Nutrition
Active, not recruitingPhase 3
PREVENT HPV -Related Cancers Trial
HPV Vaccination, Uptake Vaccination

All Health Personnel Attitude trials

Study at a glance

From the registry record, last updated by the sponsor on 25 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Implementing Innovative and Strategic Approaches to Prevent and Mitigate the Deleterious Effects of HPV Across the Lifespan of Hispanics of Mexican Origin: Healthcare Provider Intervention
ClinicalTrials.gov ID: NCT05120869
Acronym / sponsor ID: 8321
Conditions: Health Personnel Attitude, Health Knowledge, Attitudes, Practice
Keywords: Healthcare Professionals, Health Personnel Knowledge, Attitudes, Practices, Healthcare Skills and Training, Human Papillomavirus Vaccination, Human Papillomavirus Cancer Screening, HPV Cancer Prevention, HPV Cancer Mitigation, Sexual and Reproductive Health
Study type: Interventional
Recruitment status: Completed
Enrolment: 161 participants (actual)
Lead sponsor: University of Texas, El PasoUniversity, hospital or other
Collaborators: National Institute on Minority Health and Health Disparities (NIMHD), Burrell College of Health Sciences
Study start: 22 Dec 2023 (actual)
Primary completion: 2 Dec 2024 (actual)
Study completion: 2 Dec 2024 (actual)
First posted: 15 Nov 2021 (actual)
Results: Posted 20 Jul 2026

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

Study design

Primary purpose: Other
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind (participant, outcomes assessor)
Number of arms: 2
Model description: A parallel trial design will be used to examine the effectiveness of a tailored HPV education and professional skills intervention. Emerging and current healthcare providers will be randomly assigned to one of two conditions: 1) treatment condition in which they will receive a tailored Education and Professional Skills Intervention, and 2) control condition in which they will receive general, publicly available information about HPV and communication skills. Participants will then be followed over time and the responses will be compared between groups.

Arm	Type	Receives
Treatment	Experimental	Behavioral: Tailored HPV Education and Professional Skills Intervention GroupA tailored HPV education and professional skills intervention.
Control	Active comparator	Behavioral: General HPV Education and Communication Skills Control GroupGeneral/publicly available educational materials on HPV and communication skills.

Who may qualify

Ages: 18 to 65 years
Sex: All
Healthy volunteers: Accepted
Age groups: Adult, Older adult

Key inclusion criteria (3 listed)

Current (in practice) or emerging (in training - medical student, resident, or fellow) healthcare provider
Working/training or living in the El Paso U.S.-Mexico Border Region (i.e., El Paso County, TX-Southern New Mexico)
Have the authorization to recommend/prescribe/administer the HPV vaccine

Key exclusion criteria (5 listed)

Unaffiliated with the El Paso U.S.-Mexico Border Region (i.e., El Paso County, TX-Southern New Mexico)
Participation in Phases I or II of the larger research project [cross-sectional phases]
Does not identify as a current or emerging healthcare provider
Declines or is unable to participate in the full intervention and follow-up time-points
Unable to complete participation and activities in the English language

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Tailored HPV Education and Professional Skills Intervention GroupThe provider education and professional skills intervention will involve audio and visual content and will be delivered in the English language.	Behavioural	Treatment
General HPV Education and Communication Skills Control GroupThe general provider education intervention will involve audio and visual content and will be delivered in the English language.	Behavioural	Control

Primary outcome

Healthcare Provider (HCP) Practices Scale Score
Time frame: Baseline
Healthcare provider practices score were assessed using an 8-item Healthcare Provider (HCP) Practices scale from the Healthcare Personnel Survey. The scale evaluated healthcare providers' HPV vaccine recommendation practices, HPV screening recommendation practices, and communication practices. Items were scored on a 5-point Likert scale ranging from Never (1) to Always (5). Healthcare provider practices score is the average score over the 8 items, ranging from 1 to 5, with higher scores indicating better (more frequent engagement in recommended healthcare provider practices related to HPV prevention and screening).
Healthcare Provider (HCP) Practices Scale Score
Time frame: 3 months post intervention
Healthcare provider practices score were assessed using an 8-item Healthcare Provider (HCP) Practices scale from the Healthcare Personnel Survey. The scale evaluated healthcare providers' HPV vaccine recommendation practices, HPV screening recommendation practices, and communication practices. Items were scored on a 5-point Likert scale ranging from Never (1) to Always (5). Healthcare provider practices score is the average score over the 8 items, ranging from 1 to 5, with higher scores indicating better (more frequent engagement in recommended healthcare provider practices related to HPV prevention and screening).
Healthcare Provider (HCP) Practices Scale Score
Time frame: 6 months post intervention
Healthcare provider practices score were assessed using an 8-item Healthcare Provider (HCP) Practices scale from the Healthcare Personnel Survey. The scale evaluated healthcare providers' HPV vaccine recommendation practices, HPV screening recommendation practices, and communication practices. Items were scored on a 5-point Likert scale ranging from Never (1) to Always (5). Healthcare provider practices score is the average score over the 8 items, ranging from 1 to 5, with higher scores indicating better (more frequent engagement in recommended healthcare provider practices related to HPV prevention and screening).

2 secondary outcomes

Human Papillomavirus (HPV) Attitude Score
Time frame: Immediately post-intervention (0 months).
Human Papillomavirus (HPV) Knowledge Score
Time frame: Immediately post-intervention (0 months).

Results and safety

Results posted to the registry on 20 Jul 2026, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Treatment	62	55
Control	75	66

Primary outcome: Healthcare Provider (HCP) Practices Scale Score

Time frame: Baseline. Mean (Standard Deviation). Unit: scores on a scale

Measure	Treatment n = 55	Control n = 66
Value	4.48 (1.59)	3.91 (1.70)

Treatment vs Control: Mean Difference (Net): 1.0023 (95% CI -5.6381 to 7.6428), p = 0.7679, Mixed Models Analysis

Population analysed: Loss of follow-ups

Primary outcome: Healthcare Provider (HCP) Practices Scale Score

Time frame: 3 months post intervention. Mean (Standard Deviation). Unit: scores on a scale

Measure	Treatment n = 34	Control n = 34
Vaccinated	4.77 (1.41)	4.41 (1.73)

Treatment vs Control: Mean Difference (Net): 1.6932 (95% CI -6.1289 to 9.5152), p = 0.6724, Mixed Models Analysis

Population analysed: Loss of follow ups.

Primary outcome: Healthcare Provider (HCP) Practices Scale Score

Time frame: 6 months post intervention. Mean (Standard Deviation). Unit: scores on a scale

Measure	Treatment n = 23	Control n = 24
Value	4.75 (1.54)	4.44 (1.83)

Treatment vs Control: Mean Difference (Net): 1.7462 (95% CI -6.0758 to 9.5682), p = 0.6628, Mixed Models Analysis

Population analysed: Loss of follow ups

2 secondary outcomes are reported in the full results.

Adverse events

Time frame: adverse event data were not collected. Other adverse events reported at 0% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Treatment	0 of 0	0 of 0	0
Control	0 of 0	0 of 0	0

Limitations and caveats (from the sponsor): Participant retention decreased at later follow-up assessments, resulting in missing data at some post-intervention time points. The reduced sample size for follow-up analyses may limit statistical power and the precision of effect estimates.

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 25 Aug 2026.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Background: PubMed 16500736Brabin L, Roberts SA, Farzaneh F, Kitchener HC. Future acceptance of adolescent human papillomavirus vaccination: a survey of parental attitudes. Vaccine. 2006 Apr 12;24(16):3087-94. doi: 10.1016/j.vaccine.2006.01.048. Epub 2006 Feb 9.
Background: PubMed 19940807McRee AL, Brewer NT, Reiter PL, Gottlieb SL, Smith JS. The Carolina HPV immunization attitudes and beliefs scale (CHIAS): scale development and associations with intentions to vaccinate. Sex Transm Dis. 2010 Apr;37(4):234-9. doi: 10.1097/OLQ.0b013e3181c37e15.
Background: PubMed 21966351Katz ML, Krieger JL, Roberto AJ. Human papillomavirus (HPV): college male's knowledge, perceived risk, sources of information, vaccine barriers and communication. J Mens Health. 2011 Oct 1;8(3):175-184. doi: 10.1016/j.jomh.2011.04.002.
Derived from this study: PubMed 40179382Martinez J, Cordero JI, Whitney M, LaRoche KL, Frietze G, Moya EM, Gosselink K. Web-Based Human Papillomavirus Education and Professional Skills Intervention for Health Care Providers: Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2025 Apr 3;14:e60790. doi: 10.2196/60790.
NIH RePORTER for 2U54MD007592-26 8321Link provided by the sponsor.
Individual participant dataSharing planned: Yes. Collected deidentified individual participant data (IPD), all IPD that underlie results in a publication.

Related trials for Health Personnel Attitude

Not yet recruiting
Be Well at Work-Plus: A Depression and Physical Activity Intervention for Hospital Service Workers (Aim 3)
Depression, Physical Inactivity
Recruiting
Trial of Social Work Services in Fracture Clinic Setting
Orthopaedic Fractures, Socioeconomic Factors
Recruiting
A Study Of Resilience And Mental Well-Being Through Breathing Practice For Clinical Care Professionals
Burnout, Healthcare Workers, Breathing Exercises
Recruiting
Climate-Responsive Nutrition, WASH, and Heat Counselling for Maternal and Child Health in Sindh, Pakistan
Maternal Nutrition, Child Nutrition
Active, not recruitingPhase 3
PREVENT HPV -Related Cancers Trial
HPV Vaccination, Uptake Vaccination

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Eva M Moya, PhD, LMSW principal investigator

The University of Texas at El Paso, Border Biomedical Research Center

2 sites in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 20 Jul 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Healthcare Provider (HCP) Practices Scale Score (time frame: Baseline). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05120869, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Aug 2026.